Stiris Research Inc. awarded a Phase IIa Venous Leg Ulcer Study

London, ON — April 3, 2017 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces that a Canadian biotechnology company has awarded them the US component of their global Phase IIa Venous Leg Ulcer trial. Stiris will launch the US component with the company alongside their global pharmaceutical partner. This trial will be conducted in US and Europe.

Venous leg ulcers contribute to over 80% of all lower extremity ulcerations, affecting approximately 1% of the US population. These ulcerations are usually recurrent and can last for weeks or even years. They can lead to serious health complications if left untreated (American Family Physician, 2010).

“Stiris is looking forward to working with this novel treatment in order to improve the healing time of these ulcerations in patients. Most treatment options for leg ulcerations include compression therapy, elevation, dressings and pentoxifylline; we are excited to see the improvements this treatment will bring,” said Amanda Carrera, Vice President.

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.